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Abstract 
Purpose: The study was designed to investigate the effects of a novel spironolactone chalcone in the 
prevention of peritoneal fibrosis. 
Methods: Wistar rats (n = 30) were randomly assigned to 3 groups: bacteria (B), spironolactone amide 
treatment (S), and control (C) groups. C group received only dextran beads while S and B groups were 
given bacteria and dextran beads intraperitoneally, but spironolactone chalcone was also given to S 
group. The treatments were administered daily. The rats were sacrificed on day 15 to quantify peritoneal 
adhesion and for histological examination of the peritoneal tissues using hematoxylin, eosin and 
Masson’s trichrome dyes. Enzyme-linked immunosorbent assay (ELISA) kit was used to determine 
TGFβ1 content of peritoneal fluids and serum samples. 
Results: Spironolactone chalcone treatment at a dose of 30 mg/kg body weight daily for 15 days 
significantly reduced peritoneal total adhesion score in S group compared to untreated B group (p < 
0.01). S group also showed significantly lower mean peritoneal thickness, inflammation score, and 
fibrosis score compared to B group. Serum transforming growth factor β1 was also reduced significantly 
in S group animals on spironolactone chalcone treatment compared to B group. 
Conclusion: Spironolactone chalcone is a potentially effective candidate for decreasing the extent of 
peritoneal injury caused by bacterial peritonitis. 
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Changes are induced in the peritoneal 
membrane due to the bio-incompatible 
components present in dialysis solution and 
frequent peritonitis episodes [1-4]. In peritoneal 
dialysis (PD) there is extracellular matrix 
accumulation, submesothelial fibrosis and 
decrease in ultrafiltration capacity [5].  
 
Renin angiotensin aldosterone system in 
association with cytokine transforming growth 
factor β is responsible for tissue repair [6-8]. It is 
reported that the peritoneal membrane damage 
is however prevented by angiotensin converting-
enzyme inhibitors and angiotensin II receptor 
blockers [9-11]. There is improvement in 
prognosis of kidney injury patients using 
mineralocorticoid receptor antagonist [12,13]. PD 
complication, peritonitis [14] involves infective 
organism mediated inflammatory cytokines and 
interaction of resident cell populations of 
macrophages, mesothelial cells, and fibroblasts 
[15,16]. Increased submesothelial thickness, 
collagen deposition, increased cellularity, along 
with increased neovascularization in peritoneal 
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tissue were observed in an inflammatory model 
after one week [17]. It is believed that growth 
factors and cytokines secreted by mesothelial 
cells, macrophages, and fibroblasts are 
associated with peritoneal fibrosis [18,19]. 
 
Efforts have been made to prevent peritoneal 
fibrosis in PD patients using various drugs and 
chemicals to inhibit peritoneal mesothelial cell 
proliferation and/or matrix formation[20]    [21–
24]. 
 
In the present study, the efficacy of 
spironolactone chalcone (Fig 1), an analogue of 
spironolactone in the prevention of peritoneal 
fibrosis in a rat experimental model of bacterial 










A total of 30 male Wistar rats (aged, 8-10 weeks 
from the Animal Center of the Chinese Academy 
of Sciences, Shanghai, China) were housed in 
Animal house with a 12 h light/dark cycle. The 
study was approved by the Institutional Animal 
Committee of Shanghai University and in 
accordance with the Regulation for Animal 
Experiments of the University and Fundamental 
Guidelines for Proper Conduct of Animal 
Experiments and Related Activities in Academic 
Research Institutions under the jurisdication of 
the Ministry of Education, Culture, Sports, 




Fresh 6-9 h Staphylococcus aureus strain ATCC 
25923 (American Type and Culture Collection, 
Rockville, Maryland, USA) cultures in a brain–
heart infusion broth (Oxoid, Basingstoke, UK) 
were prepared in an agitated water bath at 37 
°C. To determine the actual inoculum sizes serial 
dilutions were prepared. Dextran beads 
(Cytodex; Sigma Chemicals, St Louis, Missouri, 
USA) were added to the bacterial suspensions 




Thirty rats were randomly assigned into 3 groups 
of 10 each: bacteria (B), bacteria + 
spironolactone chalcone (S), and control (C) 
groups. Rats in B and S groups were 
intraperitoneally given bacteria mixed with 
dextran beads whereas the Group C received 
only dextran beads via a 1 mL tuberculin syringe. 
Spironolactone chalcone at a dose of 30 mg/kg 
body weight was given daily to group S rats for 
15 days via an oro-gastric tube.  
 
On 15th day after ketamine anesthesia treatment 
peritoneal fluid was collected from the rat 
peritoneal cavity. The fluid was centrifuged (4 °C, 
12000 rpm for 20 min) to remove insoluble 
particles and the supernatants were stored at -50 
°C. Then laparotomy was performed and the 
gross adhesion scoring system was used to 
assess the extent of peritoneal adhesion. Three 
mL blood samples were collected from the vena 
cava caudalis and serum samples were stored at 
-50 °C. After sacrifice peritoneum, liver, small 
intestine, and abdominal wall tissue samples 
were taken from the injection site. 
 
Morphological and histological analysis of 
the peritoneal cavity 
 
For evaluation of peritoneal adhesion score, 
most prominent adhesion sites which include site 
between the liver and omentum, omentum and 
intestinal wall, intestine and the abdominal wall, 
and intestine and the stomach were selected. 
Complete absence of adhesion was assigned a 
zero score; 1 to 3 separate adhesions a score of 
1 and 3 indicate distinctly separate adhesions 





The formalin fixed and paraffin-embedded 
tissues samples together with peritoneum were 
cut into 2 mm thick slices and stained with 
hematoxylin & eosin and Masson’s trichrome 
dyes. After deparafinization the sections were 
examined under light microscope. Absence of 
inflammation was assigned score 0; mild 
inflammation score 1; moderate inflammation 
score 2; and severe inflammation score 3. The 
presence of fibrosis was evaluated 
semiquantitatively from Masson’s trichrome-
stained sections: score 0, small scattered areas 
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of green staining; score 1, thin bands of green 
staining; score 2, thicker, connected bands of 





Enzyme-linked immunosorbent assay kit 
(Promega, Madison, Wisconsin, USA) was used 
to determine the content of TGF-β1 in peritoneal 




The results are expressed as mean ± SD. SPSS 
11.0 software (SPSS Inc, Chicago, Illinois, USA) 
was used for statistical analysis, Kruskal–Wallis 
test for continuous variables, and Mann–Whitney 
test with Bonferroni correction; the later was 
used for post hoc analysis. Spearman’s rank test 
was used for correlation among the parameters. 
Differences were considered statistically 




Peritoneal adhesion scoring system  
 
The semi quantitative analysis of total peritoneal 
adhesion score revealed a zero score in the 
control group. However the total peritoneal 
adhesion score was significantly higher in the B 
group (4.54 ± 1.03) compared to that in the 
control group (0). The score for the S group was 
close to that of the control group (0.34 ± 0.02). 
 
Histological analysis  
 
The examination of peritoneal thickness of three 
different sites showed that the liver surface 
thickness (Fig 2) was significantly lower in the S 
(2.21 ± 0.41 mm) and C (1.87 ± 0.35 mm) groups 
compared to that of the B group (402.37 ± 
301.87 mm). Mean peritoneal thickness of 
intestinal wall was lower in the treatment S group 
(14.18 ± 2.78 mm) than in the B group (911.36 ± 
298.46 mm). In control group the level of 
peritoneal thickness was significantly lower 
(12.23 ± 2.67 mm). The examination of the mean 
peritoneal thickness of abdominal wall also 
showed lower thickness of the S group (37.23 ± 
2.98 mm) compared to that in the B group 
(184.87 ± 73.43 mm). It was significantly lower 
only in the control group (32.76 ± 2.82 mm) 
compared to the B group (p < 0.05). 
 
Analysis of the data from three peritoneal 
locations showed that the values for mean 
peritoneal inflammation, mean peritoneal fibrosis, 
and mean peritoneal thickness were significantly 
higher in the B group compared to the control 
group. The values of mean peritoneal 
inflammation in the B, S and C groups were 2.04 
± 0.65, 0.13 ± 0.03 and 0.10 ± 0.01 respectively. 
The values of mean peritoneal fibrosis were 2.34 
± 0.71, 0.48 ± 0.12 and 0.34 ± 0.10 whereas the 
values of mean peritoneal thickness were 502.23 
± 159.93, 15.34 ± 43 and 13.67 ± 1.86 mm in the 
B, S and C groups respectively  (p < 0.05). Mean 





Analysis of the level of TGFβ1in peritoneal 
washing fluid and serum of the rats from the B, S 
and C group showed that the level was 
significantly higher in B group compared to that 
in the C group. However the level of TGFβ1in 
both the peritoneal washing fluid and serum in 
the S group was close to that of the C group 
(Table 1). 
 
Table 1: The level of mean transforming growth factor 
β1 (TGFβ1) in peritoneal washing fluids and serum 
 




Bacteria (B) 5.69 ± 0.87 60.32 ± 5.34 
Spironolactone (S) 2.32 ± 1.36 19.45 ± 4.03 




Fig 2: Masson’s trichrome-stained peritoneum sections demonstrate fibrotic thickening between the mesothelium 
and the liver surface in the B (bacterial), S (spironolactone chalcone) and C groups (control) 
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Fig 3: Mean peritoneal thickness in the B (bacterial), S 




In PD patients, the episodes of peritonitis are the 
major cause which leads to peritoneal fibrosis. In 
our study, a rat model of Staphylococci induced 
peritoneal fibrosis and vehicle enhanced 
peritonitis was used to investigate the effect of 
spironolactone chalcone on peritoneal fibrosis. 
The results revealed absence of peritoneal 
adhesion scores in the control group whereas the 
score in B group was significantly higher. 
Treatment of the rats with spironolactone 
chalcone resulted in a significant decrease in 
peritoneal adhesion scores and the score was 
close to that of the control group. This 
demonstrates the potential of spironolactone 
chalcone in preventing the effects of peritonitis.  
 
We observed that mean peritoneal thickness in 
the B group was significantly higher compared to 
control group, suggesting the efficacy of the 
experimental model in damaging the peritoneal 
membrane. Additionally, the lower peritoneal 
adhesion scores and thinner peritoneum in rats 
given spironolactone chalcone than those of the 
B group demonstrate that these drugs were able 
to limit peritoneal injury due to acute bacterial 
peritonitis. In spironolactone chalcone treatment 
group the mean peritoneal thickness was 
significantly lower compared to that of the 
bacterial group.  
 
The analysis of individual peritoneal sites 
showed a lower peritoneal thickness in the 
treatment group than in the bacterial group. 
Comparison of the mean fibrosis and 
inflammation scores revealed similar and higher 
scores in the treatment and control group 
compared to that of the control group. Our study 
shows that the spironolactone amide used was 
able to limit peritoneal damage due to bacterial 
peritonitis. Our results from the analysis of 
TGFβ1 level in peritoneal washing fluid and 
serum of the rats demonstrated that the levels of 
TGFβ1 were significantly decreased on 
spironolactone chalcone treatment compared to 
that in untreated bacterial group. Enhanced level 
of TGFβ1 in the rat serum is a clear indication of 




Histopathological data demonstrate that 
spironolactone amide decreases peritoneal injury 
due to bacterial peritonitis. Therefore, 
spironolactone amide may be useful in the 
prevention of peritoneal injury suffering peritonitis 
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